Castle Biosciences Inc (CSTL)

$21.06

+1.75

(+9.06%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $19.16
    $21.07
    $21.06
    downward going graph

    9.02%

    Downside

    Day's Volatility :9.07%

    Upside

    0.05%

    downward going graph
  • $12.07
    $25.91
    $21.06
    downward going graph

    42.69%

    Downside

    52 Weeks Volatility :53.42%

    Upside

    18.72%

    downward going graph

Returns

PeriodCastle Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-5.06%
6.5%
0.0%
6 Months
-11.14%
7.1%
0.0%
1 Year
24.5%
9.8%
0.0%
3 Years
-70.84%
14.2%
-20.2%

Highlights

Market Capitalization
548.0M
Book Value
$14.59
Earnings Per Share (EPS)
-1.13
Wall Street Target Price
34.33
Profit Margin
-12.28%
Operating Margin TTM
-7.5%
Return On Assets TTM
-5.92%
Return On Equity TTM
-7.82%
Revenue TTM
250.7M
Revenue Per Share TTM
9.28
Quarterly Revenue Growth YOY
73.6%
Gross Profit TTM
105.0M
EBITDA
-29.1M
Diluted Eps TTM
-1.13
Quarterly Earnings Growth YOY
-0.93
EPS Estimate Current Year
-1.61
EPS Estimate Next Year
-1.91
EPS Estimate Current Quarter
-0.33
EPS Estimate Next Quarter
-0.68

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Castle Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 63.01%

Current $21.06
Target $34.33

Company Financials

FY18Y/Y Change
Revenue
22.8M
↑ 65.67%
Net Income
-6.4M
↓ 48.53%
Net Profit Margin
-27.94%
↑ 61.99%
FY19Y/Y Change
Revenue
51.9M
↑ 127.62%
Net Income
5.3M
↓ 182.88%
Net Profit Margin
10.17%
↑ 38.11%
FY20Y/Y Change
Revenue
62.6M
↑ 20.79%
Net Income
-10.3M
↓ 294.88%
Net Profit Margin
-16.42%
↓ 26.59%
FY21Y/Y Change
Revenue
94.1M
↑ 50.18%
Net Income
-31.3M
↑ 204.28%
Net Profit Margin
-33.26%
↓ 16.84%
FY22Y/Y Change
Revenue
137.0M
↑ 45.65%
Net Income
-67.1M
↑ 114.55%
Net Profit Margin
-48.99%
↓ 15.73%
FY23Y/Y Change
Revenue
219.8M
↑ 60.38%
Net Income
-57.5M
↓ 14.41%
Net Profit Margin
-26.15%
↑ 22.84%
Q4 FY22Q/Q Change
Revenue
38.3M
↑ 3.59%
Net Income
-20.6M
↑ 9.61%
Net Profit Margin
-53.78%
↓ 2.95%
Q1 FY23Q/Q Change
Revenue
42.0M
↑ 9.65%
Net Income
-29.2M
↑ 41.64%
Net Profit Margin
-69.47%
↓ 15.69%
Q2 FY23Q/Q Change
Revenue
50.1M
↑ 19.27%
Net Income
-18.8M
↓ 35.7%
Net Profit Margin
-37.45%
↑ 32.02%
Q3 FY23Q/Q Change
Revenue
61.5M
↑ 22.65%
Net Income
-6.9M
↓ 63.23%
Net Profit Margin
-11.23%
↑ 26.22%
Q4 FY23Q/Q Change
Revenue
66.1M
↑ 7.52%
Net Income
-2.6M
↓ 62.64%
Net Profit Margin
-3.9%
↑ 7.33%
Q1 FY24Q/Q Change
Revenue
73.0M
↑ 10.37%
Net Income
-2.5M
↓ 1.78%
Net Profit Margin
-3.47%
↑ 0.43%
FY18Y/Y Change
Total Assets
22.4M
↑ 128.15%
Total Liabilities
32.5M
↑ 34.79%
FY19Y/Y Change
Total Assets
119.7M
↑ 434.46%
Total Liabilities
34.6M
↑ 6.65%
FY20Y/Y Change
Total Assets
439.3M
↑ 266.88%
Total Liabilities
23.6M
↓ 31.75%
FY21Y/Y Change
Total Assets
462.6M
↑ 5.29%
Total Liabilities
50.8M
↑ 115.05%
FY22Y/Y Change
Total Assets
447.3M
↓ 3.3%
Total Liabilities
48.2M
↓ 5.22%
FY23Y/Y Change
Total Assets
477.8M
↑ 6.81%
Total Liabilities
86.5M
↑ 79.63%
Q4 FY22Q/Q Change
Total Assets
447.3M
↓ 2.29%
Total Liabilities
48.2M
↑ 3.88%
Q1 FY23Q/Q Change
Total Assets
426.9M
↓ 4.57%
Total Liabilities
41.7M
↓ 13.36%
Q2 FY23Q/Q Change
Total Assets
425.4M
↓ 0.35%
Total Liabilities
46.6M
↑ 11.71%
Q3 FY23Q/Q Change
Total Assets
436.0M
↑ 2.5%
Total Liabilities
50.2M
↑ 7.73%
Q4 FY23Q/Q Change
Total Assets
477.8M
↑ 9.58%
Total Liabilities
86.5M
↑ 72.27%
Q1 FY24Q/Q Change
Total Assets
458.5M
↓ 4.04%
Total Liabilities
56.0M
↓ 35.24%
FY18Y/Y Change
Operating Cash Flow
-12.3M
↑ 0.5%
Investing Cash Flow
-277.0K
↓ 81.34%
Financing Cash Flow
15.8M
↑ 78.63%
FY19Y/Y Change
Operating Cash Flow
7.0M
↓ 157.06%
Investing Cash Flow
-937.0K
↑ 238.27%
Financing Cash Flow
88.3M
↑ 457.44%
FY20Y/Y Change
Operating Cash Flow
9.9M
↑ 40.63%
Investing Cash Flow
-4.7M
↑ 406.72%
Financing Cash Flow
305.9M
↑ 246.47%
FY21Y/Y Change
Operating Cash Flow
-19.0M
↓ 292.43%
Investing Cash Flow
-66.7M
↑ 1303.9%
Financing Cash Flow
5.4M
↓ 98.23%
FY22Y/Y Change
Operating Cash Flow
-41.7M
↑ 119.43%
Investing Cash Flow
-166.5M
↑ 149.85%
Financing Cash Flow
1.5M
↓ 72.05%
Q4 FY22Q/Q Change
Operating Cash Flow
-6.0M
↑ 14.85%
Investing Cash Flow
-4.5M
↓ 96.66%
Financing Cash Flow
-750.0K
↓ 293.3%

Technicals Summary

Sell

Neutral

Buy

Castle Biosciences Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Castle Biosciences Inc
Castle Biosciences Inc
-8.44%
-11.14%
24.5%
-70.84%
-16.01%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-3.67%
-10.34%
-15.37%
-31.35%
65.77%
Agilent Technologies Inc.
Agilent Technologies Inc.
1.42%
3.05%
5.07%
-10.16%
94.22%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
6.51%
8.62%
3.5%
12.36%
106.99%
Danaher Corp.
Danaher Corp.
6.51%
15.92%
1.97%
-6.92%
89.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
10.0%
7.5%
0.14%
-6.07%
45.29%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Castle Biosciences Inc
Castle Biosciences Inc
NA
NA
NA
-1.61
-0.08
-0.06
NA
14.59
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
45.67
45.67
4.75
11.06
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
31.63
31.63
2.7
5.2
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.72
35.72
2.81
21.71
0.14
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
48.76
48.76
3.13
6.99
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.13
30.13
1.33
11.19
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Castle Biosciences Inc
Castle Biosciences Inc
Buy
$548.0M
-16.01%
NA
-12.28%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$38.8B
65.77%
45.67
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.9B
94.22%
31.63
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$219.4B
106.99%
35.72
14.2%
Danaher Corp.
Danaher Corp.
Buy
$191.9B
89.83%
48.76
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.3B
45.29%
30.13
9.39%

Insights on Castle Biosciences Inc

  • Increasing Revenue

    Revenue is up for the last 12 quarters, 22.75M → 72.97M (in $), with an average increase of 9.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -29.20M → -2.53M (in $), with an average increase of 99.2% per quarter

  • Vs TMO

    In the last 3 years, Castle Biosciences Inc has experienced a drawdown of -70.8%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 60.6%

Institutional Holdings

  • BlackRock Inc

    9.40%

  • Wasatch Advisors LP

    9.24%

  • Granahan Investment Management Inc..

    5.89%

  • Principal Financial Group Inc

    5.55%

  • Vanguard Group Inc

    5.41%

  • Bellevue Group AG

    4.42%

Company Information

castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.

Organization
Castle Biosciences Inc
Employees
638
CEO
Mr. Derek J. Maetzold
Industry
Health Technology

Discover More

FAQs